Point72 Asset Management, L.P. 13F: Adds $26M to BBNX Stake

Point72 Asset Management has significantly increased its stake in Beta Bionics, Inc. (NasdaqGM: BBNX), according to the latest Form 13F filing with the SEC. The firm boosted its holdings by 1,537,689 shares, a 155.7% increase, bringing its total to 2,525,040 shares. The value of this position is approximately $40.17 million, as of the reporting period.

What Changed in Point72's Beta Bionics Position

Point72 Asset Management added 1,537,689 shares to its Beta Bionics holdings, marking a 155.7% increase from its previous count of 987,351 shares. This significant addition brings the firm's total to 2,525,040 shares, valued at about $40.17 million.

Other Institutional Activity in Beta Bionics

Other institutional investors also adjusted their positions in Beta Bionics. Eventide Asset Management grew its holdings by 950,760 shares, ending with 5,945,488 shares worth around $59.57 million. Soleus Capital Management increased its stake by 1,819,936 shares, now holding 4,354,501 shares valued at $43.63 million. Morgan Stanley added 768,181 shares to reach a total of 4,227,634 shares, valued at approximately $42.36 million. Conversely, Farallon Capital Management reduced its holdings by 706,000 shares, resulting in 3,607,920 shares valued at $36.15 million.

Beta Bionics, Inc. Stock Down 22.3%

Shares of Beta Bionics traded near $15.91 on Friday. The company, which specializes in medical devices, has a market cap of about $709 million. It currently lacks a meaningful P/E ratio due to negative earnings, with an EPS of -$1.37. The stock's 52-week range is between $8.80 and $32.71, with a 50-day moving average of $11.95 and a 200-day moving average of $18.34. The company's current ratio stands at 10.69, indicating strong liquidity.

Recent Earnings

Beta Bionics reported revenue of $110.24 million, showing a growth rate of 56.6%. However, the company posted a net margin of -60.3% and a return on equity of -22.7%. The next earnings report is expected on July 21, 2026.

Analysts Set New Price Targets

Analysts have maintained their ratings on Beta Bionics with several firms setting various price targets. On May 27, 2026, Goldman Sachs maintained a 'buy' rating with a $17 price target. B of A Securities also maintained a 'hold' rating with an $11 target on May 18, 2026. The consensus among analysts is a 'buy' recommendation, with an average target price of $19.18 based on 11 opinions.

About Beta Bionics

Beta Bionics, Inc. is a healthcare company based in Irvine, California. It focuses on developing medical devices to improve the lives of people with diabetes. The company offers the iLet Bionic Pancreas, an insulin delivery device, and is working on other innovative solutions like the Patch Pump and Bihormonal iLet. Led by CEO Sean T. Saint, Beta Bionics employs around 420 people and collaborates with partners like Xeris Pharmaceuticals and Abbott Diabetes Care.

Bottom Line

Point72 Asset Management's substantial increase in Beta Bionics shares highlights growing institutional interest in the company. While the 13F filing reflects past holdings and not necessarily current positions, it indicates confidence in Beta Bionics' potential. Investors will watch for the upcoming earnings report and any changes in analyst ratings for further insights.